Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Ended early

BioPolyMOF polyMOFs as promising drug delivery systems for antimicrobial therapy

Coordinator
Fundacion IMDEA Energia, Spain
Runs
1 January 2023 to 30 June 2025
Status
Ended early
EU funding
€226k
Total cost
—
Partners
3 organisations in 3 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101061833

What the project is doing

In the project's own words, from its summary on CORDIS.

The combination of metal organic frameworks (MOFs) and polymers is highly desirable since both contribute with outstanding features (high and defined porosity and crystallinity as well as tunable mechanical and chemical properties, respectively). In particular, they represent an appealing strategy in the field of drug delivery systems (DDS): i) the polymer can increase the chemical and colloidal stability of the DDS; ii) the polymer can present itself biological activity (e.g. antimicrobial) and stimuli response (e.g. pH, temperature); iii) the metal centers of the MOFs can exhibit intrinsic bioactivity (e.g.

Zn2+, Cu2+, Fe3+) and iv) the MOF porosity can adsorb and progressively release exceptional cargoes of complementary active ingredients. Mostly associated as composite or core-shell, the coordination of the polymer as a building block to the metallic part of the MOF (polyMOF) is almost unexplored. Until now, only 10 polyMOFs (over 90,000 MOFs) have been reported, and all of them being in the exploratory phase, with no demonstrated potential applications.

In this sense, highly robust polyMOFs will be here prepared based on polymers-containing polycomplexant ligands (instead of molecular polydentate ligands) and bioactive cations, stablishing a platform for the development of a library of polyMOFs with innovative combined antimicrobial properties. As proof of concept, the in vitro safety and potential activity of these novel polyMOFs will be evaluated for the challenging antimicrobial therapy.

Finally, the scale-up and potential technology transfer of the most promising prototypes will be assessed within an industrial placement at Immaterial Ltd.

Topics

Who is involved

OrganisationCityCountryRole
Fundacion IMDEA EnergiaMostoles MadridSpainCoordinator
Mof Apps ASOsloNorwayAssociatedpartner
University of GlasgowGlasgowUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI